As many as 17 percent of people have had a near-death experience and these events can permanently affect a person’s life.

The first published virus-based gene therapy for SYNGAP1 deletion yields benefits despite the gene’s long length and complexity.

The Anthem Award recognizes work that drives positive impact and change